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Abstract
The clinical course of chronic hepatitis C virus (HCV) 
infection is characterized by possible development 
of both liver and extrahepatic disorders. The tropism 
of HCV for the lymphoid tissue is responsible for 
several immune-mediated disorders; a poly-oligoclonal 
B-lymphocyte expansion, commonly observed in a 
high proportion of patients with HCV infection, are 
responsible for the production of different autoantibodies 
and immune-complexes, such as mixed cryoglobulins. 
These serological alterations may characterize a variety 
of autoimmune or neoplastic diseases. Cryoglobulinemic 
vasculitis due to small-vessel deposition of circulating 
mixed cryoglobulins is the prototype of HCV-driven 
immune-mediated and lymphoproliferative disorders; 
interestingly, in some cases the disease may evolve to 
frank malignant lymphoma. In addition, HCV shows an 
oncogenic potential as suggested by several clinico-
epidemiological and laboratory studies; in addition to 
hepatocellular carcinoma that represents the most 
frequent HCV-related malignancy, a causative role of 
HCV has been largely demonstrated in a significant 
percentage of patients with isolated B-cells non-
Hodgkin’s lymphomas. The same virus may be also 
involved in the pathogenesis of papillary thyroid cancer, 
a rare neoplastic condition that may complicate HCV-
related thyroid involvement. Patients with HCV infection 
are frequently asymptomatic or may develop only 
hepatic alteration, while a limited but clinically relevant 
number can develop one or more autoimmune and/or 
neoplastic disorders. Given the large variability of their 
prevalence among patients’ populations from different 
countries, it is possible to hypothesize a potential role of 
other co-factors, i.e. , genetic and/or environmental, in 
the pathogenesis of HCV-related extra-hepatic diseases. 
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Hepatitis C virus syndrome: A constellation of organ- and 
non-organ specific autoimmune disorders, B-cell non-
Hodgkin’s lymphoma, and cancer
Core tip: The proposed definition of hepatitis C virus 
(HCV) syndrome encompasses the multiform complex 
of clinico-pathological conditions potentially correlated 
to chronic HCV infection. The natural history of HCV 
syndrome is the result of multifactorial and multistep 
pathogenetic process, which usually proceeds from 
mild, often isolated manifestations, to systemic 
immune-mediated disorders, and less frequently to 
overt malignancies. Here we analyze the clinical, 
epidemiological, and pathogenetic aspects of this 
multifaceted condition, including the updated results of 
the world literature.
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INTRODUCTION
Hepatitis C virus (HCV) has been isolated in 1989; it 
represents the main agent of the so-called nonA/nonB 
chronic hepatitis[1]; soon after the HCV discovery, 
several clinico-epidemiological, pathological, and 
laboratory studies definitely evidenced the role of this 
agent in the symptom complex associated to mixed 
cryoglobulinemia (MCs)[2-4]. Clinically, MCs is systemic 
autoimmune disorder, also termed cryoglobulinemic 
vasculitis (CV), characterized by cutaneous and 
visceral organ involvement, including chronic hepatitis 
present in a relevant number of patients[4-7]. The 
presence of liver involvement, rarely found in systemic 
vasculitis, suggested a role of hepatotropic viruses 
in CV since the seventies[4,6,7]; this hypothesis was 
ultimately confirmed by the high rate of HCV ongoing 
infection in large CV patients’ series[2-4,8]. On the other 
hands, MCs mimics some immune-mediated disorders 
and malignancies, especially B-cell non-Hodgkin’
s lymphoma (B-NHL); this peculiar clinical feature 
suggested a possible role of HCV also in other immune-
mediated and neoplastic conditions during the past 
two decades[4,6,7]. Besides liver involvement, a growing 
number of clinico-laboratory studies progressively 
evidenced a possible pathogenetic role of chronic HCV 
infection in various extrahepatic manifestations, among 
which the MCs represents the true prototype[4,6,7].
In this complex scenario, the demonstration of 
HCV lymphotropism represented a decisive advance 
in the knowledge of the pathogenesis of HCV-
associated disorders[9,10]. The spectrum of these 
conditions includes both hepatic, organ-specific and 
systemic autoimmune disorders, and malignancies[4,6,7]; 
therefore we previously proposed the term “HCV 
syndrome” referring to this constellation of virus-
driven clinical conditions[11]. The different clinical 
phenotypes of HCV-syndrome can be the results of 
genetic/environmental co-factors as suggested by the 
heterogeneous geographical prevalence of single HCV-
associated manifestations[4,6,7]. 
The present review focuses on the state of the art 
of this multifaceted condition with particular emphasis 
to extra-hepatic manifestations. 
PATHOGENESIS OF HCV SYNDROME
Numerous studies regarding the biological aspects 
of HCV and the interactions between viral genome 
with the immune system of the infected subjects may 
explain the complex clinical spectrum of HCV-associated 
disorders[4,6,7,9-16]. Soon after HCV identification, the 
hepato- and lymphotropism of this virus has been 
clearly demonstrated[9,10]; in particular, the HCV 
infection of lymphoid tissue may represent a decisive 
step in the development of virus-driven autoimmune-
lymphoproliferative diseases[4,11]. Epidemiological 
studies firstly suggested a possible pathogenetic role of 
HCV in MCs, a systemic disease sustained by indolent 
B-cell expansion[4-7]; moreover, cryoglobulinemia may 
be detected in a relevant percentage of individuals with 
HCV infection, frequently associated with circulating 
autoantibodies and/or mixed cryoglobulinemia, the 
hallmark of overt MCs[4-7,17].
A positive, single-stranded RNA characterizes 
the HCV; given the absence of a DNA intermediate 
in the viral replication, HCV RNA sequences cannot 
incorporate into the genome of infected individuals; 
consequently, it may represent a chronic stimulus to 
the immune system, which through a multistep process 
may lead to clonal B-lymphocytes expansion[4,12-15]. 
In particular, a relevant number of patients with 
HCV infection show t(14;18) translocation, which in 
turn may lead to Bcl-2 proto-oncogene activation; 
more frequently HCV-associated MCs with mono-
oligoclonal type Ⅱ mixed cryoglobulins[4,6,7,18] (Figure 
1). In addition, viral envelope E2 protein able to 
bind the molecule CD81, which is widely expressed 
on cell membrane of both hepatocytes and B-cells, 
might be decisive for HCV-associated autoimmune 
phenomena[4,6,7,19]. The interaction of HCV-E2 with 
CD81, part of cell-surface protein complex CD81-
CD21-CD19-Leu 13 on the B-lymphocytes, may be 
able to reduce the threshold for the activation of B-cells 
by bridging complement recognition CD21-mediated 
and antigen-specific recognition (4, 6, 7, 13, 14, 19). 
The HCV-E2 and CD81 interaction in antigen-reactive 
B-lymphocytes may amplify the VDJ rearrangement 
frequency[13,14]; the t(14;18) translocation represents 
one of possible genetic aberration with consequent 
activation of bcl-2 proto-oncogene detectable in HCV-
infected individuals[18]. The Bcl-2 over expression 
may prevent apoptosis and consequently may extend 
the survival B-lymphocytes[13,14,18]. The expansion of 
B-cells may lead to autoantibody production, including 
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the anti-IgG rheumatoid factor constitutive of IgG-
IgM immune-complexes, including mixed cryog-
lobulins[4,6,7,20].
While specific autoantibodies are typically found in 
patients with single-organ or systemic autoimmune 
disorders, cryoprecipitable and non-cryoprecipitable 
IgG-IgM immune-complexes are the serological 
hallmarks of MCs[4,6,7,20]. Moreover, a molecular mimicry 
mechanism that may involve specific HCV proteins and 
host autoantigens might produce B-cell activation with 
increased production of autoantibodies[4,6,7,20] (Figure 
1). While the prolonged survival of B-lymphocytes can 
lead to additional genetic aberrations, such as c-myc, 
Bcl6, and p53 responsible to the development of 
malignant B-NHL in predisposed individuals[4,6,7,12-14,20] 
(Figure 1). The HCV oncogenic potential has been 
clearly identified in hepatocellular carcinoma and in a 
relevant number of patients with B-NHL[4,6,7,12-14,20-22] 
or thyroid cancer[23,24]. Comparably to the association 
between Helicobacter pylori infection and MALT 
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Figure 1  Etiopathogenetic cascade of hepatitis C virus syndrome, including both hepatic and extra-hepatic disorders, is a multifactorial and multistep 
process: The remote events include hepatitis C virus infection, predisposing genetic factors and, possibly, unknown environmental/toxic triggers 
(Left). The HCV-driven immune-system alterations with prominent “benign” lymphoproliferation, from one side, and oncogenic alterations, from another side, may 
be the result of different pathogenetic mechanisms not mutually exclusive, through a multifactorial and multistep process: Viral antigens (core, envelope E2, NS3, 
NS4, NS5A proteins) may exert a chronic stimulus on the host immune system, the high-affinity binding between HCV-E2 and CD81 and consequent t(14;18) 
translocation with bcl-2 proto-oncogene activation, a cross-reaction between particular HCV antigens and host autoantigens, i.e., a molecular mimicry mechanism, 
and a direct infection of B-lymphocytes by HCV responsible for neoplastic cell transformation. Predisposing host factors may include particular HLA alleles, and 
both metabolic and hormonal conditions. The main consequence is a “benign” B-cell proliferation with production of various autoantibodies, among which RF and 
cryo- and non-cryoprecipitable IC. These serological alterations may be correlated with different organ- and non-organ-specific autoimmune disorders, including the 
systemic manifestations of MCs, or cryoglobulinemic vasculitis. Moreover, the activation of Bcl2 proto-oncogene, responsible for prolonged B cell survival, may be 
a predisposing condition to other genetic aberrations (c-myc, Bcl6, and p53 activation), which may lead to frank B cell lymphomas (B-NHL) and other malignancies 
(HCC: Hepatocellular carcinoma; PTC: Papillary thyroid cancer). The appearance of malignant neoplasias can be seen in a small but significant percentage of 
patients, usually as a late complication. Both immunological and neoplastic disorders show a clinico-serological and pathological overlap. Often, autoimmune organ-
specific manifestations may evolve to systemic conditions, such as mixed cryoglobulinemia syndrome, and less frequently to overt malignancies. Conversely, it is 
not uncommon that patients with malignancies develop one or more autoimmune manifestations. In this scenario, MCs is at the crossing road between autoimmune 
and neoplastic disorders; Right: There are not comprehensive therapeutical guidelines for the HCV syndrome because of the complexity of its pathogenetic and 
clinico-prognostic characteristics; we can adopt in part the therapeutical strategy used for MCs, which often encompasses the different clinical variants of HCV 
syndrome. This therapeutical approach is essentially based on three main levels of intervention: the etiological treatment by means of antiviral drugs directed at HCV 
eradication, the pathogenetic therapies with immunomodulating/antineoplastic drugs, and the pathogenetic/symptomatic therapies such as corticosteroids and plasma 
exchange (see also text). HCV: Hepatitis C virus; IC: Immune complexes; SS: Sicca syndrome; PCT: Porphyria cutanea tarda; RF: Rheumatoid factor; MCs: Mixed 
cryoglobulinemia syndrome; CPX: Cyclophosphamide.
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variants of BAFF gene promoter suggested a possible 
explanation; namely, a particular allelic variant (-871T), 
possibly correlated with the BAFF gene increased 
transcriptional activity, was significantly more frequently 
found in HCV-positive subjects with than in those 
without MCs. As regards HCV-related NHL, increased 
levels of circulating osteopontin were associated with 
HCV-positive B-cell lymphoma. Moreover, the highest 
levels of osteoponin were observed among HCV-positive 
individuals with associated MC type Ⅱ regardless the 
presence of B-NHL[15,16]. 
On the whole, HCV-infected patients represent 
one of the most useful models of study as regards 
the complex interactions between autoimmunity and 
oncogenesis in humans[4] (Figure 2).
CLINICAL MANIFESTATIONS OF HCV 
SYNDROME
The HCV biological activities, i.e., the hepato- and 
lymphotropism, are responsible for HCV syndrome, 
a mosaic of hepatic as well as organ-specific and 
systemic diseases[11] (Figures 1 and 3). 
Several clinico-epidemiological studies published in 
the world literature demonstrated that the prevalence 
of HCV-related autoimmune/neoplastic disorders 
shows a manifest geographical heterogeneity[4,6,7,25]. 
This finding does not perfectly coincide with the 
varying prevalence of HCV infection in different 
parts of the world; therefore, we can hypothesize 
that HCV alone is not sufficient to produce the wide 
spectrum of diseases that may complicate the natural 
course of HCV infection. It is supposable that specific 
HCV genotypes, host genetic and/or environmental 
factors should cooperate in the pathogenesis of HCV 
syndrome[4,6,7,26,27]; even if the actual relevance of 
these putative co-factors should be fully elucidated.
Moreover, contrasting data as regards the pre-
valence of different HCV-associated disorders has been 
also reported among clinical studies on HCV-infected 
patients’ series from the same country, depending on 
specific specialization and/or investigative approach 
(sample sizes and choice of patients and/or control 
subjects) of different referring centers (Figure 3).
It is well known that the majority of individuals 
with HCV infection are asymptomatic, often for 
long-time periods, without consequences for their 
quality of life as well as the overall outcome; while a 
limited but relevant number of subjects may develop 
hepatic as well as extrahepatic diseases, often as late 
complication (Figure 1). The prolonged clinical follow-
up of large series of HCV-positive patients suggests 
that the natural course of HCV infection may proceed 
through a multistage pathological process, usually 
from mild-moderate to clinically severe conditions, 
such as the MCs or malignant neoplasias[4,6,7] (Figures 
1 and 3). However, it is possible that the slow 
progression of HCV syndrome in some individuals may 
lymphoma of the stomach, the same pathogenetic 
mechanism of chronic antigen stimulation producing 
malignant lymphoproliferation may be hypothesized for 
HCV-driven lymphomagenesis[4,6,7,12-14] (Figure 1). This 
important topic, in particular the possible role of HCV 
infection in B-NHL, was underlined in a recent review 
focusing on the proposed epidemiologic/virological 
guidelines to support a causative role for a given virus 
in human cancerogenesis[14].
The HCV-driven lymphomagenesis may be the 
result of various oncogenetic mechanisms that may 
be not mutually exclusive, through a multifactorial 
and multistep process[4,6,7,12-14]: chronic external stimu-
lation by HCV antigens of B-cell receptors (CD19, 
CD21, CD81, B-cell receptors), in particular the high-
affinity binding of HCV-E2 and CD81 may lead to 
bcl-2 activation; HCV replication in B-lymphocytes 
with oncogenic potential through viral proteins; the 
direct infection of B-lymphocytes by HCV may produce 
permanent genetic B-cell damage, the so-called 
mutator B-cell phenotype due to “hit and run” mecha-
nism of cellular transformation. The potential role of 
viral penetration and replication in B-lymphocytes 
remains to be definitely elucidated; however, some 
studies supported the oncogenic role of HCV genome or 
viral proteins in B-lymphocytes[12-16]. 
More recently, a role of the B-cell-activating factor 
(BAFF or BLyS) in the pathogenesis of HCV-related 
lymphomagenesis has been suggested. BAFF is a 
specific cytokine of B-lymphocytes, which is essential 
for the development and survival of B-lymphocytes. A 
higher serum levels of BAFF are detectable in patients 
with HCV infection if compared to healthy controls, and 
more frequently in HCV-positive subjects developing 
lymphoproliferative disorders[15,16]; but the exact 
mechanisms of this enhanced concentration remain still 
to be deeply clarified. The evaluation of polymorphic 
HCV syndrome
A kaleidoscope of autoimmune and neoplastic disorders
HCV 
infection
Autoimmunity Malignancy
Figure 2  Patients with chronic hepatitis C virus infection may develop a 
complex of both hepatic and extra-hepatic disorders. Hepatitis C virus (HCV) 
syndrome represents an important example of coexistence of autoimmune 
and neoplastic conditions in humans; moreover, it can be one of the most 
useful models of study of the complex interactions between autoimmunity and 
oncogenesis[4] (Figure 2).
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be abruptly complicated by one of the most severe 
complications[4,28].
The symptom complex of HCV syndrome includes 
numerous autoimmune diseases and malignant 
neoplasias[11]. The statistical and clinical relevance of 
HCV association with different disorders is markedly 
variable; in this light, HCV-driven conditions can be 
classified in four groups according to the strength 
of association[4,11] (Table 1): level 1: the HCV is the 
etiological agent or it is present in a large percentage 
of patients; level 2: HCV is detectable in a statistically 
significant number of patients when compared to 
the general population, at least in some geographical 
areas, often demonstrated by clinical and laboratory 
investigations; level 3: a causative role of HCV has 
been suggested by some cohort studies or level 4: 
by isolated, anecdotal observations without definite 
pathogenetic link. The following paragraphs focuses 
on the main clinical and laboratory features of extra-
hepatic manifestations of HCV syndrome.
Autoimmune diseases
Extrahepatic manifestations of HCV syndrome are 
immune-mediated diseases[11]; MCs represents the 
most common condition, it represents a crossover 
between “benign” organ-specific and systemic 
autoimmune diseases, from one side, and malignant 
neoplastic disorders, from the other side[4,11] (Figure 1). 
MCs, cryoglobulinemic vasculitis: MCs is commonly 
classified among small-vessel systemic vasculitides; 
thus, the terms MCs and CV should be referred 
to the same clinico-serological and pathological 
disorder[4-7,20]. The first one underlines the presence 
of the serological hallmark, i.e., mixed cryoglobulins, 
which characterize the disease, along with the “benign” 
B-cell lymphoproliferation, and the classical symptoms, 
namely purpura, weakness, and arthralgias[4-7,20]; while 
the term CV focuses on the pathological hallmark, 
i.e., the leucocytoclastic vasculitis, affecting small-
medium sized vessels (Figure 4). Vascular damage 
is the consequence of the deposition of circulating 
cryo- and non-cryoprecipitable immune-complexes 
and complement; they produce both skin and internal 
organ damage[4-7,20] (Figures 1 and 4; Table 2 with 
MCs symptoms). CV represents a crossroads among 
immune-mediated disorders and malignancies (Figure 
1); it is not rare to observe in a single patient during 
Table 1  Hepatitis C virus syndrome: strength of association between hepatitis C virus infection and different diseases
  Strong association1 Significant association2 Possible association3 Anecdotal association4
  Chonic hepatitis B-cell NHL Sicca syndrome/SS PM/DM
  Cirrhosis Monoclonal gammopthies Polyarthritis PAN
  HCC Porphyria cutanea tarda Pruritus  Behçet’s syndrome 
  Mixed cryoglobulinemia s./ Glomerulonephritis Osteosclerosis Chronic urticaria
  Cryoglobulinemic vasculitis Autoimmune thyroiditis
Papillary thyroid cancer
Diabetes m. type 2
Fibromyalgia 
Peripheral neuropathy 
Lung alveolitis
Autoimmune hepatitis
Cardiovascular inv.
Lichen planus
Psorias
Mooren corneal ulcer
1The HCV is the etiological agent or it is detectable in the majority of patients; 2HCV is detectable in a significant proportion of pts compared to general 
population, with heterogeneous geographical distribution, its potential role is supported by pathogenetic studies; 3A role of HCV infection has been 
suggested by cohort studies or 4by some anecdotal observations. HCC: Hepatocellular carcinoma; SS: Sjögren’s syndrome; PM/DM: Polymyositis/
dermatomyositis; PAN: Panarteritis nodosa; HCV: Hepatitis C virus.
Clinico-epidemiological relevance of HCV-associated disorders
evaluated from different perspectives
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Figure 3  Schematic representation of the constellation of 
hepatitis C virus -associated disorders, varying from the 
great number of individuals with asymptomatic hepatitis 
C virus infection to patients with one or more harmful 
manifestations. Epidemiological studies demonstrated a great 
geographical heterogeneity among different HCV-associated 
disorders, as well as with important discrepancies with regards 
to their prevalence reported in clinical studies from the same 
country; this latter discrepancy may be dependent on specific 
specializations and/or variable methodological approaches 
(sample sizes, choice of patients and/or control subjects) of 
investigators from different referring centers. HCV: Hepatitis C 
virus; HCC: Hepatocellular carcinoma.
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A
B C D
E F
Figure 4  The main serological, clinical, and pathological hallmarks of mixed cryoglobulinemia syndrome, or cryoglobulinemic vasculitis: A: On the right 
serum cryoprecipitate (evaluated after 7 d storage at 4 ℃) composed by polyclonal IgG (autoantigen) and monoclonal IgMk (autoantibody) immune-
complexes, compared to normal serum sample; B: Recent onset, palpable purpuric lesions of the lower limbs; C: Sock-like ochraceous hyperpigmentation 
of the legs and feet, consequence of repeated episodes of purpura; D: Severe, necrotizing vasculitic skin lesion of the leg; E: Typical histological pattern of 
cutaneous leukocytoclastic vasculitis involving the small vessels and characterized by diffuse fibrinoid necrosis and disintegrated neutrophil permeation of 
the vessel walls; F: Wide non-healing skin ulcer, often resistant to treatment.
Mixed cryoglobulinemia syndrome
Cryoglobulinemic vasculitis
After 7 d at + 4 ℃
Normal
serum
IgG-lgMk
cryoprecipitate
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the natural course of the disease the entire spectrum of 
symptoms, from mild manifestations to overt vasculitic 
syndrome, and finally to most severe complications 
such as hepatic/renal failure, and/or cancer[4,28]. 
Compared to other systemic vasculitides, CV shows 
two distinctive symptoms, namely B-cell NHL and 
chronic hepatitis. While B-cell NHL affects a minority 
of patients (Table 2), generally as late complication, 
liver involvement is detectable in almost 3/4 of 
individuals[4-7,20]. The clinical course of chronic hepatitis 
is generally mild to moderate, and often asymptomatic 
for long time period; it may be complicated by cirrhosis 
and in some cases by hepatocellular carcinoma[4,28]. 
Renal involvement, usually a type Ⅰ membranopro
liferative glomerulonephritis, represents one of the 
most severe organ damage of CV[4,28,29]. Moreover, 
the rare, diffuse vasculitis is a life-threatening com-
plication prognostically similar to classical systemic 
vasculitides[4,28]. Laboratory investigations are 
characterized by largely variable amounts of serum 
cryoglobulins and low complement with typically 
marked C4 reduction and normal C3; nonetheless, 
levels of cryocrit and complement are frequently 
not correlated with the severity/activity of CV[4]. 
Typically, B-lymphocyte expansion represents the 
substrate of CV, which in a number of patients may be 
complicated by overt lymphoma, usually a late disease 
manifestation[4,28,30]. The large majority of patients with 
CV show a chronic HCV infection; this association is 
particularly frequent in particular geographical areas, 
mainly Southern Europe[4]; generally in those countries 
where the presence of other HCV-associated extra-
hepatic disorders are rather observed[4,25]. Conversely, 
other classical systemic vasculitides are significantly 
more frequent in other countries of Northern Europe 
and Northern America where HCV-associated CV is less 
frequently observed[4,31]. 
Other systemic rheumatic diseases: CV is charac-
terized by clinical polymorphism; therefore it is not 
rare to observe a clinical overlap between CV and other 
rheumatological disorders, mainly Sjögren’s syndrome 
or rheumatoid arthritis[4,28,31-35] (Table 1, Figure 1). 
Chronic arthritis, generally oligoarthritis, can develop 
during the natural course of HCV infection; the joint 
involvement commonly appears as non-erosive, less 
aggressive arthritis. HCV-associated MCs patients may 
develop mild oligoarthritis, on the contrary moderate-
severe polyarthritis, comparable to classical rheumatoid 
arthritis, may be sporadically observed in HCV-infected 
patients treated with alpha-interferon[4,31,32]. On the 
other hand, given the relatively high prevalence of 
these conditions, we can observe a pure association of 
HCV infection with frank rheumatoid arthritis; the same 
association can be occasionally observed with primary 
Sjögren’s syndrome. While the possible involvement 
of HCV in the pathogenesis of Sjögren’s syndrome is 
still a controversial topic[4,31-35]. Differential diagnosis 
between CV and primary Sjögren’s syndrome may be 
very difficult in individual cases such patients with sicca 
syndrome, serum mixed cryoglobulins, HCV infection, 
and anti-RoSSA/LaSSB antibodies; these latter 
generally at low serum concentration[4,31-35]. This peculiar 
symptom complex that may satisfy classification criteria 
of both CV and primary Sjögren’s syndrome seems 
to identify a worse clinical variant, more frequently 
complicated by malignant lymphoma[31-35]. In these 
instances, it is preferable to consider these individuals 
as having Sjögren’s/MCs overlapping disease that 
should be treated according to individual clinical 
manifestations[31,32]. 
The presence in the clinical practice of overlapping 
MC/Sjögren’s suggests that HCV may trigger com-
plex immunological alterations that, in genetically 
predisposed subjects, may cause various clinical 
phenotypes mimicking some well-known disorders, 
such as rheumatoid arthritis, Sjögren’s syndrome, and 
dermato-polymyositis[4,31,32] (Figure 3, Table 1).
Actually, the clinical value of other rheumatic 
disorders possibly triggered by HCV observed in limited 
patients’ series or anecdotal case reports deserve 
further investigations[4,31,32] (Table 1).
Endocrine disorders: Thyroiditis, diabetes type 2, 
and male gonadal dysfunction can be included among 
Table 2  Clinico-epidemiological and laboratory features of 
mixed cryoglobulinemia1
  Epidemiological features
     Mean age at disease onset ± SD, yr (range) 55 ± 12 (29-72)
     Mean disease duration ± SD, yr (range) 12 ± 10 (1-40)
     Female/male ratio   3
  Clinical features
     Purpura 98
     Weakness 98
     Arthralgias 91
     Arthritis (non-erosive)   8
     Raynaud’s phenomenon 32
     Sicca syndrome 51
     Peripheral neuropathy 81
     Renal involvement2 31
     Liver involvement 73
     B cell non-Hodgkin’s lymphoma 11
     Hepatocellular carcinoma   3
  Serological and virological features
     Mean cryocrit (SD) 4.4% (12)
     Type Ⅱ/type Ⅲ mixed cryoglobulins 2/1
     Mean C3 (SD) (nv 60-130 mg/dL) 93 (30)
     Mean C4 (SD) (nv 20-55 mg/dL) 10 (12)
     Anti-nuclear antibodies 30
     Anti-mitochondrial antibodies   9
     Anti-smooth muscle antibodies 18
     Anti-extractable nuclear antigen antibodies   8
     Anti-HCV antibodies ± HCV RNA 92
     Anti-HBV antibodies 32
     HBsAg   1
1Data are referred to 100 consecutive, unselected Italian patients with mixed 
cryoglobulinemia syndrome (MCs) evaluated at the end of follow-up; 
2Membranoproliferative glomerulonephritis type I. HCC: Hepatocellular 
carcinoma; HCV: Hepatitis C virus.
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the most frequent endocrine alterations that may 
complicate HCV-positive individuals with and without 
MCs[4,31,36,37]. 
The same geographic heterogeneity that chara-
cterizes different disorders complicating HCV infection 
is reported for the prevalence of serum levels of anti-
thyroid antibodies, which markedly varied from 2% to 
48% of individuals in several cohort studies[36,38]. 
A possible explanation of this heterogeneity may be 
related to the variable contribution of environmental 
factors and host genetic predisposition among different 
patients’ populations, for example the iodine intake or 
the presence of other infectious factors[11,36,38]. 
In addition, hypothyroidism can be found in 2%-9% 
of subjects with HCV infection, generally as subclinical 
finding[36]; while various thyroid disorders and anti-
thyroid antibodies are generally more frequently 
detected in hepatitis type C compared to hepatitis B 
or D[36]. In fact, the prevalence of these findings has 
been evaluated in a wide patients’ series with type C 
hepatitis compared to general population groups from 
geographical areas with variable iodine intake and 
subjects with hepatitis type B[36]. Hypothyroidism and 
autoimmune thyroiditis were found in patients with 
type C hepatitis in a statistically higher percentage 
if compared to control subjects; while comparable 
percentages of hyperthyroidism were detected. 
Comparable findings have been reported in another 
study evaluating thyroid alterations in HCV-associated 
MCs[36-38]. 
Overall, thyroid involvement can be considered as 
one of possible manifestations of MCs as well as of 
HCV syndrome[4,31,36-38].
Thyroid involvement should be periodically evalu-
ated in HCV-infected patients to early diagnose 
the thyroid dysfunction and the possible malignant 
complications[36].
Diabetes type 2 can be considered another relevant 
endocrine disorder of the HCV syndrome, generally 
not correlated with presence/severity of hepatic 
involvement[36]. Preliminary, clinico-epidemiological 
studies reported an increased prevalence of diabetes 
type 2 in HCV-infected non-cirrhotic subjects compared 
with chronic hepatitis of different origin, a finding not 
confirmed in a subsequent report[36]. Successively, a 
case control study evaluated 564 Italian HCV-infected 
non-cirrhotic patients compared with 302 control 
individuals without history of drug or alcohol addiction, 
or positive for viral hepatitis serological markers, and 
82 HBV-infected non-cirrhotic subjects[36]. Diabetes 
type 2 was significantly more frequent in HCV-infected 
non-cirrhotic patients compared to controls (12.6% vs 
4.9% and 7%, respectively; P = 0.008). Of interest, 
prevalence of diabetes type 2 in HBV-infected non-
cirrhotic subjects (7%) resulted within the age-
adjusted range of prevalence rates for the Italian 
general population (4%)[36].
The clinical phenotypes of subjects with hepatitis 
and diabetes type 2 were quite different: individuals 
with non-cirrhotic HCV-positive diabetes type 2 were 
slightly older, with higher levels of triglycerides, 
blood pressure, and BMI, but lower concentrations of 
cholesterol HDL[36].
In addition, HCV-positive, non-cirrhotic subjects 
with diabetes type 2 had significantly lower BMI 
compared to control subjects with diabetes type 
2 alone and significantly higher BMI (P < 0.05) 
compared to non-cirrhotic, non-diabetic HCV-infected 
subjects. Classical diabetes type 2 is characterized by 
the “metabolic syndrome” phenotype, i.e., overweight, 
older age, higher arterial pressure, and dyslipidemia. 
Conversely, non-cirrhotic, non-diabetic HCV-infec-
ted subjects resulted lean and with low levels of 
cholesterol LDL. These latter have been correlated with 
the hypobetalipoproteinemia induced by the binding 
competition of HCV with hepatocyte LDL receptors[36]. 
Patients with HCV chronic infection manifested a 
peculiar clinical variant different from the usual form 
of diabetes type 2. The classification of HCV-positive 
patients as diabetes type 2 is quite traditional; with 
the new pathogenetic information the boundaries 
between diabetes type 1, latent autoimmune diabetes, 
HCV-driven organ-specific autoimmunity
thyroiditis and type 2 diabetes
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Figure 5  Immune-mediated thyroid involvement 
and diabetes type 2 can be observed in a significant 
percentage of patients with hepatitis C virus infection. 
The figure summarizes the possible etiopathogenetic 
mechanisms involved in these two endocrine disorders. 
HCV thyroid infection may act by upregulating CXCL10 
gene expression and secretion in thyrocytes (and pancreatic 
b-cells); CXCL10 may promote the recruitment of Th1 
lymphocytes, which secrete interferon-g (IFN-g) and tumor 
necrosis factor-α (TNFα). In turn, these cytokines may 
induce CXCL10 secretion by thyrocytes (and pancreatic 
b-cells), thus perpetuating the immune cascade. The 
consequence may be the appearance of thyroid autoimmune 
disorders and/or diabetes type 2 in genetically predisposed 
subjects. HCV: Hepatitis C virus.
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and diabetes type 2 are progressively weakening. In 
patients with HCV-associated MCs complicated by 
diabetes, an immune-mediated mechanism has been 
postulated for the endocrine disorder; a comparable 
autoimmune pathogenesis might be suggested also 
for diabetes observed in HCV-infected patients without 
MCs. This supposition is reinforced by the increasing 
observation of autoimmune alterations in patients 
with diabetes type 2[36,39-47]. HCV-related MCs patients 
showed abnormal serum levels of sex hormones[48]. 
Interestingly, erectile dysfunction was anecdotally 
observed in subjects with type C during antiviral 
treatment with interferon-alpha[49]. The putative 
relationship between HCV infection and gonadal 
dysfunction has been evaluated in 207 HCV-infected 
males (102 with MCs) in comparison with 207 age- 
and sex-matched individuals, selected randomly from 
2010 subjects of Italian general population previously 
evaluated for the presence of erectile dysfunction[50]. 
The study adopted some important exclusion criteria, 
namely patients’ age over 55 years, recent treatment 
with interferon-alpha, presence of cardio-vascular and 
psychiatric disorders, diabetes, hypothyroidism, and 
renal failure.
HCV-positive patients showed a higher prevalence 
of erectile dysfunction compared to controls (P < 
0.001). In addition, abnormally low testosterone 
plasma levels were detected in HCV-infected indivi-
duals with complicating erectile dysfunction. Of 
interest, erectile dysfunction as well as low serum 
testosterone was independent of the severity of 
hepatic damage. The alterations of sex hormones 
along with the frequent peripheral neuropathy might 
explain the erectile dysfunction[4,31,32]. 
The above-mentioned findings are in keeping 
with the hypothesis of a possible role of patient’s 
hormonal status in immune mediated conditions 
triggered by HCV infection; we could hypothesize 
that low androgen levels may reduce endogenous 
depressive activity and consequently may amplify the 
proliferation of autoreactive B-lymphocytes triggered 
by HCV infection[4,31,32]. With regards the pathogenetic 
mechanisms responsible for HCV-related thyroid 
disorders, possibly HCV infection of thyrocytes may 
act by upregulating gene expression and secretion of 
CXCL10 (as previously shown in human hepatocytes) 
by recruiting Th1 lymphocytes, which secrete IFNg 
and tumor necrosis factor alpha (TNF-a)[40,41]. 
In turn, these cytokines may induce the secretion of 
CXCL10 by thyrocytes, with consequent perpetuation 
of the immune cascade[36] (Figure 5).
The consequence may be the appearance of 
thyroid autoimmune diseases in subjects genetically 
predisposed. This pathogenetic hypothesis has 
been confirmed by a recent study that evaluated 
the serum levels of CXCL10 in patients with HCV-
positive MCs, with and without autoimmune thyroid 
involvement[36,42], and also studying the association of 
thyroiditis with other autoimmune disorders[43-45].
Chronic immune-mediated inflammatory thyroid 
lesions may be responsible for the papillary thyroid 
cancer found in a significant number of HCV-infected 
individuals compared to controls[23,24,46].
Analogous pathogenetic mechanisms can be 
involved as consequence of HCV infection of pancreatic 
b-cells responsible for the up-regulation of CXCL10 gene 
expression and secretion[36] (Figure 5). The recruited 
Th1 lymphocytes, which secrete IFNg and TNFa, amplify 
the secretion of CXCL10 by B-lymphocytes. The final 
result is the appearance of B-cell dysfunction, with the 
probable contribution of genetic predisposition. Both 
thyroid function abnormalities and diabetes type 2 
should be considered among the manifestations of HCV 
syndrome[4,31,32,36]. 
It is opportune to evaluate these patients at 
regular intervals for the above endocrine disorders in 
order to identify subjects needing treatment and to 
early diagnose possible thyroid malignancies[47].
Porphyria cutanea tarda: Porphyria cutanea tarda 
(PCT) constitutes the most common clinical variant 
of porphyria; the disease is characterized by low 
activity of uroporphyrinogen decarboxylase (URO-D), 
the enzyme involved in the heme synthesis[51-55]. The 
URO-D deficiency is necessary but not sufficient for 
the clinical development of PCT, therefore possible 
pathogenetic co-factors have been proposed, including 
hepatotropic virus infection; this hypothesis was also 
suggested by the frequent chronic liver involvement 
in patients with PCT. Thus, the possible role of HCV 
has been investigated worldwide; numerous reports 
showed a broad range of prevalence of HCV infection 
in patients with PCT[51-55]. The HCV-associated PCT is 
particularly intriguing with regards the pathogenetic 
implications[52]. A direct role of HCV can be excluded 
considering the absence of alteration in porphyrine 
metabolism in HCV-positive patients without PCT[53]; 
while it is supposable that a cross-reactivity between 
host and HCV antigens and/or metabolic factors such 
as altered genes connected with iron metabolism[52] 
may contribute to a genetically-driven reactivity that 
may be relevant in individuals with PCT.
Renal involvement: Renal involvement represents 
a frequent complication of HCV-related MCs, which 
may seriously affect the overall outcome of these 
patients[4,28,29,31,32]. Glomerulonephritis is the result 
of immune complex glomerular deposition, mainly 
cryoglobulins. The actual pathogenetic relevance 
of HCV in the etiopathogenesis of glomerulonephritis 
remains not completely established; the detection of viral 
sequences in immune-complexes suggested an indirect 
role of HCV in the glomerular inflammation[4,28,29,31,32]. 
Moreover, a role of HCV has been suggested for 
tubulo-interstitial and glomerular renal damage in 
both transplanted and native kidney[56,57]. HCV-related 
glomerular injury may include different pathological 
patterns: mainly membranoproliferative glomeru-
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lonephritis (MPGN) in the presence/absence of 
cryoglobulinemia, while membranous nephropathy, 
rapidly progressive GN, immunotactoid and fibrillary 
GN, exudative-proliferative GN were less frequently 
observed[4,29]. Classical cryoglobulinemic type I MPGN 
is found in a significant proportion of HCV-associated 
MCs, while “primary” or clinically isolated MPGN is 
detected in less than one third of HCV-associated 
MPGN[56]. The latter variant has been observed mainly 
in Japan and United States[29,56,58]. Nevertheless, 
the actual prevalence of MPGN in HCV-positive 
patients without serum cryoglobulinemia is difficult 
to evaluate; possibly this condition may constitute 
a mild or subclinical variant of MCs, probably due 
to methodological difficulties in detecting circulating 
cryoglobulins[4]. It is not rare that MPGN is one of 
presenting symptoms of HCV-associated MCs, while 
the overt syndrome can appear as late manifestation of 
HCV infection[4,28]. Therefore, HCV-positive patients with 
apparently isolated GN should undergo to careful clinico-
serological assessment in order to exclude possible 
hepatic and extrahepatic disorders, especially the MCs. 
Miscellanea: Miscellanea of immune-mediated 
disorders may complicate HCV infection (Table 1); 
the association of lichen planus, in particular oral 
lesions, with HCV has been reported with a variable 
geographic prevalence[59,60]. Moreover, a wide number 
of mucocutaneous manifestations, generally as acute 
episode or chronic manifestation of well-known 
cutaneous diseases, are observed with variable 
prevalence in HCV-infected patients, often as limited 
series or anecdotal case reports[4,59,60] (Table 1). 
These symptoms may be the expressions of immune-
mediated skin damage, triggered by viral proteins and 
possibly amplified by interferon-alpha treatment[4]. 
Peripheral nerve involvement is a frequent HCV-
related manifestation, more often in patients with 
CV[4,61]; while involvement of central nervous system 
(CNS) is rarely observed. Vascular symptoms that may 
involve CNS may represent late manifestations of HCV 
syndrome, generally as comorbidities in subjects with 
particularly severe extra-hepatic symptoms treated 
with long-term corticosteroids. HCV-infected individuals 
may develop cardiovascular complications, which are 
not constantly confirmed by different studies[4,62,63]. 
Another controversial feature of HCV syndrome is 
the putative role of this virus in autoimmune hepa-
titis[4,31,32,64,65]. Circulating mixed cryoglobulins and 
some extrahepatic manifestations such as sicca 
syndrome, arthritis, and thyroiditis, can be observed in 
patients with autoimmune hepatitis; vice versa, HCV-
infected patients may show serum non organ-specific 
autoantibodies[11,65]. Often, antigenic specificity of 
autoantibodies detectable in HCV-positive individuals 
presents only titer differences when compared to those 
found in “primary” autoimmune hepatitis[4,11]. Possibly, 
the heterogeneity of geographical distribution of HCV-
associated autoimmune hepatitis[25] can be correlated 
to the variable cooperation of different causative 
agents, including HCV; therefore, this virus might be 
responsible for a distinct subset of AIH in infected 
individuals from specific geographical areas.
Neoplastic disorders
Following the discovery of HCV the oncogenic role 
of this virus has been established by several clinico-
epidemiological and laboratory studies; besides 
hepatocellular carcinoma, HCV chronic infection may 
represent the trigger factor of papillary thyroid cancer 
and B-cell NHL. 
Hepatocellular carcinoma: Hepatocellular carcinoma 
(HCC) is a primary hepatic cancer and occurs 
commonly as late complication of chronic hepatitis 
and cirrhosis[21,22]. Over the past two decades, the 
incidence of this malignancy is steeply increasing, 
analogously to the HCV prevalence worldwide[21,22]. 
In HCV-infected individuals HCC represents the most 
frequent malignancy[21,22]. The development and 
progression of HCC is a multistep process; a chronic 
insult, i.e., HCV, HBV, and alcohol, induces liver injury 
through oxygen species production, cellular DNA 
damage, endoplasmic reticulum stress, and necrosis 
of damaged hepatocytes. In this context, chronic 
inflammation and oxidative DNA damage favor the 
accumulation of mutations and epigenetic aberrations 
in hepatocytes or liver stem cells, which in turn may 
foster the development of dysplastic nodules and 
their malignant transformation to overt HCC[21,22]. 
This harmful complication can appear in the context 
of isolated type C hepatitis, as well as in patients with 
extrahepatic HCV-related manifestations[4,21,22]; even 
if the prevalence of HCC seems to be lower in HCV-
associated MCs compared to the entire population of 
HCV-infected patients[4,28]. This intriguing topic needs 
to be confirmed by wider clinico-epidemiological 
investigations. Tentatively, it is possible that in patients 
with HCV-related extrahepatic diseases the rather 
frequent involvement of particular HCV genotypes such 
as the 2a/2b[4,26] and/or genetic background, as well 
as a different clinical course of the disease, including 
specific treatments such as immunomodulating drugs, 
may counteract the risk for developing this tumor.
Papillary thyroid cancer: Papillary thyroid cancer 
represents a rare neoplasia that may be associated 
to chronic HCV infection[23,24]. A significantly increased 
prevalence of thyroid cancer in type C hepatitis as 
well as in HCV-related MCs compared with controls 
was first noticed in 1999[23,46]; it was subsequently 
confirmed by a case control study reporting an 
increased prevalence of HCV infection in individuals 
with papillary thyroid cancer undergoing surgery[24]. In 
addition, high prevalence of papillary thyroid cancer in 
subjects with a past history of blood transfusions and/
or liver disease seems to indirectly support the role of 
HCV in this malignancy[36]. However, a review of the 
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literature shows discordant results, possibly owing to 
important epidemiological and methodological bias[36,66]. 
A recent study on large cohort of HCV-positive patients 
seem to confirm the increased prevalence of papillary 
thyroid cancer by excluding some possible biases such 
as iodine intake, gender and/or patients’ age[36]. In our 
studies, thyroid autoimmune alterations were more 
commonly found in patients developing thyroid papillary 
cancer irrespective of whether they had type C hepatitis 
alone or HCV-related MCs[23,24,46]. This observation 
suggests that immune-mediated thyroid alterations per 
se may be a predisposing condition for this malignancy. 
Although a possible causative role of HCV infection 
in papillary thyroid cancer is suggested by the above 
clinico-epidemiological studies, this association needs to 
be verified by further investigations.
B-cell NHL: Over the last two decades a putative 
role of HCV in B-lymphocyte lymphomagenesis has 
been progressively investigated considering the 
following observations: the lymphotropism of HCV 
was definitely demonstrated in individuals chronically 
infected, including those with HCV-related MCs[9,10]; 
in the same time, HCV revealed as the major 
etiological factor of MCs, a “benign” autoimmune-
lymphoproliferative diseases that may be complicated 
by frank B-cell lymphomas[4,6,7,28,30,67,68]. Thus, the 
logical supposition was that the same virus might be 
also involved in the etiopathogenesis of ‘idiopathic’ 
B-cell NHL. In 1994, unexpected high rate of HCV 
ongoing infection in Italian series of patients with 
‘idiopathic’ B-NHL was first reported[69]. Since this 
initial report numerous clinico-epidemiological and 
laboratory studies on different patients populations 
and in animal models, plainly established the causative 
role of this virus in a significantly higher percentage 
of patients with B-NHL compared to controls[69-103]. 
Once more, this association showed a geographical 
heterogeneity similarly to that observed for other 
HCV-associated diseases, especially the MCs; in fact, 
the association between HCV and B-cell lymphomas 
was not confirmed by other epidemiological 
studies[104-119]. This particular virus-related malignant 
lymphoproliferation may presents two major clinical 
variants: B-NHL as neoplastic manifestation of HCV-
positive MCs, more often as late disease manifestation, 
or B-NHL complicating HCV infection without relevant 
extrahepatic manifestations[4,6,7,31,67,68]. The B-NHL of 
cryoglobulinemic patients can vary from extranodal, 
nodal or splenic marginal-zone lymphoma to diffuse 
large B-NHL or, less frequently, lymphoplasmacytic 
lymphoma/immunocytoma (LPL/Ic) and B-cell chronic 
lymphocytic leukemia (B-CLL)[4,120]. Lymphomas 
may be correlated to the expansion of peripheral 
B-lymphocytes and to lymphoid cell infiltrates frequ-
ently detectable in bone marrow and liver of patients 
with MCs[4,120]. These infiltrates containing lymphoid 
elements closely comparable to those characterizing 
B-CLL and LPL/Ic have been classified as “early 
lymphomas”[4,120]. However, different from overt 
malignant lymphomas, they usually remain stable 
for a long time and are followed by frank lymphatic 
malignancy in about 10% of individuals[4,120]. 
According to the above clinico-pathological features 
the term “monotypic lymphoproliferative disorder 
of undetermined significance (MLDUS)” has been 
proposed[4,120]. Interestingly, MLDUS observed in 
HCV-positive type II MC shows a significantly high 
incidence in those countries also characterized by 
frequent association between “idiopathic” B-NHL and 
HCV infection, as well as by rather high prevalence of 
genotype 2a/2c[4,120].
With regard to primary B-NHL a number of epidemio-
logical studies (Table 3) confirmed the association of 
these malignancies with HCV in a significant proportion 
of patients; HCV-associated B-NHL showed the same 
geographical heterogeneity observed for other HCV-
related extrahepatic disorders[69-119]. This epidemiological 
feature may reflect the multifactorial etiopathogenesis, 
including both genetic background and environmental 
cofactors, of this heterogeneous group of lymphatic 
malignancies[12-15]. Moreover, some discordant data 
among studies from the same country might be the 
consequence of recruitment bias (choice of patients 
and/or control subjects, sample sizes) at different 
referring centers as aforementioned (Figure 3). Whether 
an increased risk for all B-cell NHL is associated with 
HCV infection or only particular subtypes remains still 
open question[98]. Apart from the above epidemiological 
aspects, HCV can be included among other well known 
lymphotropic viruses, namely human T lymphotropic 
virus type I, Epstein Barr virus, human herpesvirus 8, 
and human immunodeficiency virus, responsible for a 
significant proportion of B-cell NHL[121]. Of interest, some 
meta-analysis studies of epidemiological investigations 
confirmed the strongly positive association between 
HCV infection and increased risk of B-NHL[90,98,122,123]. 
Finally, in HCV-infected patients with splenic marginal 
zone or indolent B-cell NHL, combined treatment with 
interferon-alpha and ribavirin may lead to HCV clearance 
and concomitant regression of lymphomas[124-126]. These 
observations clearly presuppose that the virus is the 
causative agent in at least some NHL subsets by directly 
driving the B-cell lymphoproliferation.
TREATMENT OF HCV SYNDROME
Considering the complexity of HCV syndrome because 
of its variable composition of clinical symptoms 
with specific pathogenetic, clinical, and prognostic 
characteristics, it is impossible to draw comprehensive 
therapeutical guidelines. In clinical practice, it can be 
useful to look at the therapeutical strategy developed 
for patients with MCs, which takes into account the 
different clinical variants of HCV syndrome[4,28,31,32]. 
This strategy is essentially based on three main levels 
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of intervention (Figure 1): the etiological treatment by 
means of antiviral drugs directed at HCV eradication, 
the pathogenetic therapies with immunomodulating-
antineoplastic drugs, and the pathogenetic/symp-
tomatic therapies such as corticosteroids and plasma-
pheresis[4,28,31,32]. These three different therapeutic lines 
are not mutually exclusive; they are usefully employed 
in HCV-positive MCs, considering the composition 
and severity of clinical features observed in the single 
patient[4,28,31,32] (Figure 1). The etiological treatment, 
alone or in combination with immunosuppressors, may 
lead to HCV eradication and MCs remission[31,127-134]; 
as above mentioned the beneficial effect of HCV 
eradication is also observed in patients with B-cell NHL, 
as isolated condition or complicating the MCs[124-126]. 
In theory, antivirals should be regarded as the gold 
standard treatment in patients with overt HCV-
associated clinical symptoms, considering the whole 
individual patient condition and the potential side 
effects or contraindications to these therapies[4,127-131]. 
The preemptive use of the novel direct antiviral drugs 
in HCV-infected individuals even in the absence of 
relevant clinical manifestations is a very critical issue, 
considering the necessary cost-benefit analysis. 
On the other hand, clinico-biological parameters 
predictive of possible recovery of immune-system 
alterations after HCV eradication are still lacking. 
Combined pathogenetic and symptomatic therapies 
may be able to improve a single clinical manifestation 
of HCV syndrome; the clinical usefulness of these 
treatments has been largely reported in cryoglo-
bulinemic patients, particularly for patients treated with 
anti-CD20 monoclonal antibody therapy[130,132-134]. In 
all cases, etiological, pathogenetic, and symptomatic 
treatments, in sequence or in combination, should 
be tailored on the single patient after a careful 
clinical evaluation[4,31,131-134]. Finally, long-term clinical 
monitoring of HCV-infected patients, including 
those with mild or asymptomatic clinical variants, is 
mandatory for a timely diagnosis and treatment of the 
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Table 3  Association between hepatitis C virus infection and B-cell non-Hodgkin’s lymphoma: Epidemiological studies
  Significant association1 No association1
  Ref. Country Prevalence2 Ref. Country Prevalence2
  Ferri et al[69] Italy 34% (17/50) Brind et al[104] United Kingdom 0% (0/63)
  Luppi et al[70] Italy 42% (29/69) Hanley et al[105] United Kingdom 0% (0/72)
  Mazzaro et al[71] Italy 28% (56/199) McColl et al[106] Scotland 0% (0/110)
  Musolino et al[72] Italy 20.8% (5/24) Thalen et al[107] The Netherlands 0% (0/115)
  Silvestri et al[73] Italy 8.9% (42/470)  Ellenrieder et al[108] Germany 4.3% (3/69)
  De Rosa et al[74] Italy 22.4 (59/263) Timoraglu et al[109] Turkey 0% (0/48)
  Zuckerman et al[75] Mexico and United States 22% (26/120) Collier et al[110] Canada 0% (0/101)
  Catassi et al[76] Italy 11.2% (16/143) Shariff et al[111] Canada 2.3% (2/88)
  Kashyap et al[77] United States 11.5% (36/312) Udomsakdi-Auewarakul et al[112] Thailand 2.3% (3/130)
  Luppi et al[78] Italy 22.3% (35/157) Hausfater et al[113] France 1.83% (3/164)
  Cucuianu et al[79] Romania 29.5% (20/68) Isikdogan et al[114] Turkey 0% (0/119)
  Vallisa et al[80] Italy 37.1% (65/175) Giannoulis et al[115] Greece 1.9% (2/108)
  Paydas et al[81] Turkey 11.4% (26/228) Sonmez et al[116] Turkey 2.8% (3/109)
  Harakati et al[82] Saudi Arabia 21.4% (12/56) Okan et al[117] Turkey 3.1% (8/258)
  Mizorogi et al[83] Japan 17% (17/100) Park et al[118] South Korea 2.1% (5/235)
  Zucca et al[84] Switzerland 9.4% (17/180) Varma et al[119] India 1.75% (1/57)
  3Pioltelli et al[85] Italy 16% (48/300)
  Sanchez Ruiz et al[86] Spain 11.7% (9/77)
  Chindamo et al[87] Brazil 8.2% (9/109)
  De Renzo et al[88] Italy 17.3% (39/227)
  Imai et al[89] Japan  13.4% (21/156)
  Gisbert et al[90] Spain 7% (7/99)
  Mele et al[91] Italy 17.5% (70/400)
  Yenice et al[92] Turkey 7.1% (6/84)
  Iwata et al[93] Japan 11% (16/145)
  Gisbert et al[94] Spain 5.8% (5/86)
  Talamini et al[95] Italy 19.6% (44/225)
  Cowgill et al[96] Egypt 42% (95/227)
  Engels et al[97] United States 3.9% (32/813)
  de Sanjose et al[98] Spain 3.9% (172/4784)
  Spinelli et al[99] Canada 2.4% (19/795)
  Chuang et al[100] Taiwan 11% (31/346)
  Libra et al[101] Italy 19.7% (539/2736)
  Kang et al[102] South Korea 2.8% (76/3932)
  Nosotti et al[103] Italy 9.2% (19/207)
  Range  2.4%-42% 0%-4.3%
1Compared to controls; 2HCV-RNA and/or anti-HCV; 3The prevalence of HCV infection in B-NHL was statistically significant compared to controls, but 
not confirmed by odds ratio method to estimate the relative risk. HCV: Hepatitis C virus.
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most severe complications.
CONCLUSION
The hepato- and lymphotropism are the distinctive 
biological features of HCV responsible for a wide 
symptom complex including both hepatic and systemic 
autoimmune and neoplastic diseases. The strength 
of association largely varies among potentially HCV-
driven disorders, a well as for a specific disease among 
patients’ series from different countries. Besides liver 
involvement, HCV represents the etiological agent of 
the majority patients with MCs, and may be implicated 
in a significant proportion of other autoimmune 
disorders and B-NHL.
A putative HCV-associated disease per se may 
constitute a clinical syndrome, characterized by a 
spectrum of clinico-serological variants; these latter 
can be regarded as the resulting phenotypes of a 
multifactorial and multistep process secondary to 
a variable combination of genetic, environmental, 
and infectious factors. In this context, HCV can 
be considered as one of possible causative agents 
producing distinct autoimmune or neoplastic disease 
subsets. Considering the frequent clinical overlap and 
the presence of multiple serum autoantibodies, it is 
frequent very difficult to make the differential diagnosis 
among “idiopathic” and HCV-associate autoimmune 
disorders. 
The HCV syndrome is a multifaceted condition that 
encompasses the complex of HCV-related disorders. 
The syndrome may be considered as a continuum; 
this hypothesis is frequently suggested by the clinical 
history of individual patients that may develop most of 
HCV-driven immunological/neoplastic disorders over 
their clinical follow-up. 
Future investigations should better define the 
boundaries of HCV syndrome, along with the actual 
etiopathogenetic role of this virus in different disorders 
and the involved, often unknown, co-factors, the 
effects of HCV eradication, and the correct therapeutic 
strategies for different HCV-related clinical symptoms.
Finally, considering the ongoing variations of the 
epidemiology of HCV infection and other possible 
co-factors, as well as the effects of the gradual 
improvement of therapeutical armamentarium, it is 
supposable that the spectrum of HCV syndrome, i.e., 
prevalence, clinical characteristics, and prognosis of 
different symptoms, might change over the time. The 
timely description of this evolving framework should be 
another intriguing issue of clinical investigations in the 
next future.
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